<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
 xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:owl="http://www.w3.org/2002/07/owl#"
 xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"
 xml:base="http://www.reactome.org/biopax/91/9700649#">
<owl:Ontology rdf:about="">
 <owl:imports rdf:resource="http://www.biopax.org/release/biopax-level3.owl#" />
</owl:Ontology>

<bp:Evidence rdf:ID="Evidence6">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence7">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence15">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence4">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence5">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence8">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence9">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway8">
 <bp:pathwayOrder rdf:resource="#PathwayStep14" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction7" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence14" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">alectinib-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Alectinib is a second generation tyrosine kinase inhibitor that is approved for use in ALK positive non-small cell lung cancers (NSCLCs). Alectinib is effective against a number of ALK mutants that arise after treatment with crizotinib, however resistance to alectinib has also been reported. This pathway describes ALK mutants that are resistant to inhibition with alectinib (reviewed in Lovly and Pao, 2012; Lin et al, 2017; Della Corte et al, 2018; Hallberg and Palmer, 2016).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence3">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway7">
 <bp:pathwayOrder rdf:resource="#PathwayStep12" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction6" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence12" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NVP-TAE684-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NVP TAE684 is a second generation tyrosine kinase inhibitor with activity against some ALK mutants, including some that show resistance to crizotinib (George et al, 2008; Sasaki et al, 2011; Heuckmann et al, 2011; Ceccon et al, 2013). This pathway describes ALK mutants that show resistance to inhibition by NVP TAE684.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway6">
 <bp:pathwayOrder rdf:resource="#PathwayStep10" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction5" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence10" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">brigatinib-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Brigatinib is a second generation tyrosine kinase inhibitor with activity against ALK. This pathway describes ALK mutants that are resistant to inhibition by brigatinib (reviewed in Della Corte et al, 2018; Roskoski, 2013; Lin and Pao, 2017; Hallberg and Palmer, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway5">
 <bp:pathwayOrder rdf:resource="#PathwayStep8" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction4" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence8" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ASP-3026-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ASP3026 is a second generation tyrosine kinase inhibitor with activity against ALK fusions in non-small cell lung cancers (NSCLC) and anaplastic large cell lymphomas (ALCLs). This pathway describes ALK mutants that are resistant to inhibition by ASP3026 (Amin et al, 2016; Katayama et al, 2014; George et al, 2008; Mori et al, 2014; reviewed Roskoski, 2013; Lovly and Pao, 2012)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BioSource rdf:ID="BioSource1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo sapiens</bp:name>
</bp:BioSource>

<bp:Provenance rdf:ID="Provenance1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactome</bp:name>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">http://www.reactome.org</bp:comment>
</bp:Provenance>

<bp:PathwayStep rdf:ID="PathwayStep11">
 <bp:stepProcess rdf:resource="#Pathway7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep10">
 <bp:stepProcess rdf:resource="#BiochemicalReaction5" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence10">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep13">
 <bp:stepProcess rdf:resource="#Pathway8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep12">
 <bp:stepProcess rdf:resource="#BiochemicalReaction6" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence12">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence11">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep14">
 <bp:stepProcess rdf:resource="#BiochemicalReaction7" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence14">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence13">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway4">
 <bp:pathwayOrder rdf:resource="#PathwayStep6" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction3" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence6" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">lorlatinib-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Lorlatinib is a third generation tyrosine kinase inhibitor with effectiveness against ALK and ROS rearranged cancers. This pathway describes ALK mutants that are resistant to inhibition by lorlatinib (Yoda et al, 2018; Takahashi et al, 2020; reviewed in Della Corte et al, 2018; Lin et al, 2017; Facchinietti et al, 2016).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep8">
 <bp:stepProcess rdf:resource="#BiochemicalReaction4" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction6">
 <bp:evidence rdf:resource="#Evidence13" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NVP-TAE684-resistant ALK mutants don&apos;t bind NVP-TAE684</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway3">
 <bp:pathwayOrder rdf:resource="#PathwayStep4" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction2" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence4" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">crizotinib-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Crizotinib is a type I tyrosine kinase inhibitor that is approved for treatment of ALK-positive non-small cell lung cancer. Crizotinib is also effective against ALCL and IMTs. Development of resistance to crizotinib is not uncommon, however, with patients acquiring secondary mutations or amplifications of the ALK gene that limit the effectiveness of the drug. This pathway describes ALK mutants that are resistant to crizotinib-mediated inhibition (reviewed in Roskoski, 2013; Lin et al, 2017; Della Corte et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep7">
 <bp:stepProcess rdf:resource="#Pathway5" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction7">
 <bp:evidence rdf:resource="#Evidence15" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">alectinib resistant ALK mutants don&apos;t bind alectinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway2">
 <bp:pathwayOrder rdf:resource="#PathwayStep2" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ceritinib-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ceritinib is a type I TKI that is effective against ALK driven cancers and is approved for treatment of NSCLC. Ceritinib is a second-generation TKI that shows activity against a number of crizotinib-resistant ALK alleles, however, resistance to ceritinib has also been documented. This pathway describes ALK mutants that are resistant to inhibition with ceritinib (reviewed in Lovly and Pao, 2012; Lin et al, 2017; Della Corte et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep6">
 <bp:stepProcess rdf:resource="#BiochemicalReaction3" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway1">
 <bp:pathwayOrder rdf:resource="#PathwayStep7" />
 <bp:pathwayOrder rdf:resource="#PathwayStep5" />
 <bp:pathwayOrder rdf:resource="#PathwayStep3" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1" />
 <bp:pathwayOrder rdf:resource="#PathwayStep11" />
 <bp:pathwayOrder rdf:resource="#PathwayStep13" />
 <bp:pathwayOrder rdf:resource="#PathwayStep9" />
 <bp:pathwayComponent rdf:resource="#Pathway4" />
 <bp:pathwayComponent rdf:resource="#Pathway3" />
 <bp:pathwayComponent rdf:resource="#Pathway2" />
 <bp:pathwayComponent rdf:resource="#Pathway8" />
 <bp:pathwayComponent rdf:resource="#Pathway7" />
 <bp:pathwayComponent rdf:resource="#Pathway6" />
 <bp:pathwayComponent rdf:resource="#Pathway5" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Drug resistance of ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant ALK activity arises through fusions, point mutations, overexpression or amplifications and has been shown to be an oncogenic driver in a number of cancers including anaplastic large cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), inflammatory myofibroblastic tumors (IMTs) neuroblastomas and more (reviewed in Della Corte et al, 2018; Lin et al, 2017). As a result, ALK is a promising therapeutic target for inhibition with tyrosine kinase inhibitors. Crizotinib, ceritinib, brigatinib, alectinib and lorlatinib are all approved for the treatment of ALK-driven cancers, however resistance commonly develops either as a result of accumulating secondary mutations, or through activation of bypass pathways that remove the dependence on ALK signaling (reviewed in Della Corte et al, 2017; Roskoski, 2013; Lin et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep5">
 <bp:stepProcess rdf:resource="#Pathway4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep4">
 <bp:stepProcess rdf:resource="#BiochemicalReaction2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep3">
 <bp:stepProcess rdf:resource="#Pathway3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1">
 <bp:stepProcess rdf:resource="#Pathway2" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1">
 <bp:evidence rdf:resource="#Evidence3" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ceritinib-resistant ALK mutants don&apos;t bind ceritinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction2">
 <bp:evidence rdf:resource="#Evidence5" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">crizotinib-resistant ALK mutants don&apos;t bind crizotinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction3">
 <bp:evidence rdf:resource="#Evidence7" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">lorlatinib-resistant ALK mutants don&apos;t bind lorlatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction4">
 <bp:evidence rdf:resource="#Evidence9" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ASP-3026- resistant ALK mutants don&apos;t bind ASP-3026</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep9">
 <bp:stepProcess rdf:resource="#Pathway6" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction5">
 <bp:evidence rdf:resource="#Evidence11" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">brigatinib-resistant ALK mutants don&apos;t bind brigatinib</bp:displayName>
</bp:BiochemicalReaction>
</rdf:RDF>